TST-005 is under clinical development by Transcenta and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TST-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TST-005 overview

TST-005 is under development for the treatment of solid tumors including but not limited to non-small cell lung cancer, pancreatic cancer, gastric cancer, biliary tract cancer, small-cell lung cancer, esophageal cancer, nasopharyngeal cancer, HPV associated cancer like cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, rectal cancer and bladder cancer. It is a bi-specific monoclonal antibody acts by targeting PDL1 and TGF beta. It is administered through intravenous route.

Transcenta overview

Transcenta (Transcenta Holding) that is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. The company is headquartered in Suzhou, Shanghai, China.

For a complete picture of TST-005’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.